#CTX110 - Twitter Hashtag

Jasbinder (Jessie) Chimni (My Opinions only)

about 3 years ago

Anyone aware of any other allogenic CRISPR based CAR-T for CD19 that is in or approaching a registration trial? $ CRSP #CTX110 is in discussion with the FDA regarding a registration trial. $CRBU #CB010 seems to be the only other one that I have found but it has not started a pivotal/registration trial yet.

2

9

0

3

5K

Jasbinder (Jessie) Chimni (My Opinions only)

@JessieChimni

over 3 years ago

$CRSP #CTX112, next gen of #CTX110, has also started enrolling patients with a target of enrolling up to 120 patients. #CTX112 includes the same two potency edits, Regnase-1 & TGFBRII, as #CTX131. Currently only two locations are open, I am assuming more will be opened.

JessieChimni's tweet photo. $CRSP #CTX112, next gen of #CTX110, has also started enrolling patients with a target of enrolling up to 120 patients. #CTX112 includes the same two potency edits, Regnase-1 & TGFBRII, as #CTX131. Currently only two locations are open, I am assuming more will be opened. https://t.co/zGvhuJQOuo

0

7

0

584

Jasbinder (Jessie) Chimni (My Opinions only)

@JessieChimni

over 3 years ago

$CRSP #CTX110 appears to be a global study with active recruitment across 28 cities and up to 143 patients. @CrisprSam had mentioned that this may become a single arm registration trial. It will be interesting to see how the FDA handles this trial/approval.

JessieChimni's tweet photo. $CRSP #CTX110 appears to be a global study with active recruitment across 28 cities and up to 143 patients. @CrisprSam had mentioned that this may become a single arm registration trial. It will be interesting to see how the FDA handles this trial/approval. https://t.co/mBKPKcUZoD

0

8

1

2K

Evaluate Japan @EvaluateJP

almost 5 years ago

#Crispr 社 #他家CAR_T 製剤 #CTX110 は、#Allogene 社と同様の懸念がないことが注目されたが、CTX110は短命で、最初に反応した患者の大部分が6カ月以内に再発した。同社は、再発患者に再投与し救えると主張していますが、これは現実世界では非現実的だ。https://t.co/dzUo9DpFwo #Evaluate

EvaluateJP's tweet photo. #Crispr 社 #他家CAR_T 製剤 #CTX110 は、#Allogene 社と同様の懸念がないことが注目されたが、CTX110は短命で、最初に反応した患者の大部分が6カ月以内に再発した。同社は、再発患者に再投与し救えると主張していますが、これは現実世界では非現実的だ。https://t.co/dzUo9DpFwo
#Evaluate https://t.co/mqx7i0kaOb

0

5

4

1

0

1stOncology @1stOncology

almost 5 years ago

#CRISPRTherapeutics Reports Positive Results from its Phase 1 CARBON Trial of #CTX110™ in Relapsed or Refractory #CD19+ #BCellMalignancies $CRSP https://t.co/91wiJeiajE

0

1

0

Evaluate Japan @EvaluateJP

almost 6 years ago

Crispr社の遺伝子編集された他家CAR-T製品CTX110のヒト臨床試験の最初のデータに、被験者の治療関連死が影を落とし、Crispr社の株価は14％下落した。Crispr社の最初の臨床試験は、80億ドルの時価総額のようなホームランには程遠い。 https://t.co/rPhe4kvUXc #エバリュエート #CART $CRSP #CTX110

EvaluateJP's tweet photo. Crispr社の遺伝子編集された他家CAR-T製品CTX110のヒト臨床試験の最初のデータに、被験者の治療関連死が影を落とし、Crispr社の株価は14％下落した。Crispr社の最初の臨床試験は、80億ドルの時価総額のようなホームランには程遠い。

https://t.co/rPhe4kvUXc

#エバリュエート #CART $CRSP #CTX110 https://t.co/ZHyATw61c6

0

7

3

0

BIOTECH @_B_I_O_T_E_C_H_

almost 6 years ago

Raymond James: $CRSP given the clear advantageous patient selection untaken within the CTX110 study relative to peer alloCAR T studies, we find the current 50% BORR of #CTX110 as potentially #worst #in #class $GILD $KITE $SGMO $ALLO $CLLS $DTIL

_B_I_O_T_E_C_H_'s tweet photo. Raymond James: $CRSP given the clear advantageous patient
selection untaken within the CTX110 study relative to peer alloCAR T studies, we find the current
50% BORR of #CTX110 as potentially #worst #in #class
$GILD $KITE $SGMO $ALLO $CLLS $DTIL https://t.co/SA1uBTRjdZ

1

9

3

0

BIOTECH @_B_I_O_T_E_C_H_

almost 6 years ago

Raymond James: $CRSP given the clear advantageous patient selection untaken within the CTX110 study relative to peer alloCAR T studies, we find the current 50% BORR of #CTX110 as potentially #worst #in #classic $GILD $KITE $SGMO $ALLO $CLLS $DTIL

2

13

3

0

BIOTECH @_B_I_O_T_E_C_H_

almost 6 years ago

$CRSP ONE PATIENT FROM DOSE LEVEL 4 COHORT #DIED 52 DAYS AFTER #CTX110 INFUSION

1

6

2

0

Top Tweets for #CTX110

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users